Global Cancer CDK Inhibitors Market & Clinical Pipeline 2017-2022

World News: . []

Dublin, Nov. 14, 2017 (GLOBE NEWSWIRE) -- The report has been added to offering.

The Cyclin Dependent Kinase (CDK) Inhibitors have recently emerged as one of the most promising therapeutics in the cancer pharmaceuticals segment. The progress in the scientific and technical knowledge of how the cell cycle works, pathways involved in normal and tumorous cells and the role of cyclin in tumor cell formation (Tumorigenesis) has led to an excellent boost in the research and development of special molecules or inhibitors which can prevent tumorigenic processes in effected cells.

Cyclin Dependent Kinase (CDK) Inhibitors are considered as promising and immensely effective targeted therapy of the future as it aims at targeting the tumor cell formation at its root level, before it can progress to affect other healthy cells of the body. In addition, it has opened up multiple opportunities and avenues for the life sciences industry to work upon due to the vast diversity and variations seen in the CDK pathways and their specific role and response in various types of tumors, thus suggesting the need of different types of inhibitors for different cancer therapies.Currently, Pfizer's Ibrance is the only successfully market drug that has shown impressive growth in within two years of its introduction into the cancer therapy segment. Ibrance or Palbociclib first received an accelerated approval in February 2015, becoming the first CDKs inhibitor to receive approval for breast cancer therapy. In just two years Ibrance has shown excellent growth with time which is sure to make Ibrance the dominant CDKs inhibitor in the breast cancer therapy segment.The recent advances in the discovery of newer cyclin pathways and their inhibitors have opened up new avenues in the CDKs therapy market. Multiple companies are now currently working on various therapeutics that have shown some kind of novel response in stopping or inhibiting the cell cycle. While it is obvious that Pfizer's Ibrance is currently the most effective drug in breast cancer tumor management, it is expected that Eli Lilly and Novartis are currently working on much better therapeutic having higher overall efficacy than the Ibrance.A strong clinical pipeline presents an encouraging scenario regarding the future of a particular therapeutic like the CDK inhibitor. The intense research and development in the CDK inhibitor segment has led to many of these newly discovered compounds showing excellent results in various phase of the clinical trials. While very few CDKs have come out of the clinical pipeline and showed excellent commercial success, many of the inhibitors are anticipated to be a blockbuster drug once they come out of the clinical pipeline.With the advancement in science and further knowledge about the technical know-how of the cyclin dependent kinase and cell cycle, the ability and potential of CDKs inhibitor as cancer therapeutic is bound to improve. Previous success of approved CDKs inhibitors like Ibrance has shown the immense market potential of the CDKs inhibitor market which largely remains untapped, especially in the developing countries which are bound to show an increased demand for effective cancer therapeutic like the CDKs in the future.

For more information about this report visit




CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

More news and information about Research and Markets

Published By:

Globe Newswire: 16:05 GMT Tuesday 14th November 2017

Published: .

Search for other references to "global" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2017. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers